Drug development

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #Target validation #Therapeutics

Silence For Health – Development of RNA interference based cancer therapy

Silence For Health - Development of RNA interference based cancer therapy By Dr Ansgar Santel RNA interference (RNAi) has become an invaluable tool for biomedical research. It is already routinely used as an indispensable approach for gene function analysis in basic biological research and for target identification as well as… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Target validation #Toxicology

Advances in laboratory automation for drug discovery

Advances in laboratory automation for drug discovery By Charanya Ramachandran Laboratory automation has metamorphosed the realm of drug discovery over the years through two of major influential factors – cost benefit and error reduction. Automation has reframed the traditional drug discovery process by making feasible the identification of many targets… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Imaging #RNA #Stem cells #Toxicology

PLAYING WITH TIME – Digital imaging comes of age

PLAYING WITH TIME – Digital imaging comes of age By Dr Pam Pickering Seeing dynamic intra- and extra-cellular events as they happen is central to revealing the mechanisms of disease, identifying key targets for drug intervention and assessing the impact of drug treatment on living cells. Interpreting these events through… Read More

#Archive

#Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Organic chemistry #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

The Role of Nanotechnology in Drug Discovery

By Dr Amarpreet S Dhiman In terms of drug discovery and development, the role of nanotechnology currently lies in improving diagnostic methods, developing improved drug formulations and drug delivery systems for disease therapy. The breakthrough format of nanotechnology offers innovative solutions, giving researchers greater analytical capacity, improved data quality and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Immunology #Organic chemistry #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Target validation #Therapeutics #Urinary

TR-FRET Based Assays – Getting better with age

TR-FRET Based Assays - Getting better with age By Dr John Comley Despite having been available for nearly 15 years, TR-FRET based assays are still the preferred fluorescent assay format for many screeners. A recent survey ranked Cisbio’s TR-FRET product (HTRF) as the most frequently used generic assay technology. GPCR… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Toxicology #Translational #Translational chemistry

Understanding the strategic importance of BIOMARKERS for the discovery and early development phases

Share Share Tweet Email Understanding the strategic importance of BIOMARKERS for the discovery and early development phases Understanding the strategic importance of BIOMARKERS for the discovery and early development phases By Dr Orest Hurko Biomarkers have become an increasingly hot topic in the pharmaceutical industry. How much of this is… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Metabolomics #Oncology #Orphan drugs #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

METABOLOMICS – A ‘systems’ contribution to pharmaceutical discovery and drug development

By Dr George G. Harrigan The potential of metabolomics, a systems approach to biochemical pathway analysis, to yield scientific and commercial benefits to healthcare and biotechnology enterprises is increasingly recognised. This article discusses current applications and future developments and places an emphasis on incorporation of metabolomics within all aspects of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Target validation

High Throughput Screening: meeting the challenges of more cell-based assays and HCS

High Throughput Screening: meeting the challenges of more cell-based assays and HCS By Sandra Fox, MBA The use of high content screening and cell-based assays within high throughput screening (HTS) laboratories is on the increase but there are still many challenges to overcome. Each year, HTS laboratories perform slightly more… Read More

#Archive

#ADME / Tox #Analysis #Assay development & optimisation #Biochemistry #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #PCR #Preclinical #Screening #System biology #Systems biology #Target validation

Development of an HTS FabD inhibition assay using a new 384-well filter plate to screen novel antibiotics

Development of an HTS FabD inhibition assay using a new 384-well filter plate to screen novel antibiotics by Dr Gatan Touyer, Dr Christine Miossec, and Dr Irvin Winkler Several enzymes are involved in the fatty acid biosynthesis (Fab) system of bacterial organisms. Unlike the mammalian FAS enzyme system in which… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Microfluidics #Molecular medicine #Organic chemistry #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

The Role of the Medicinal Chemist in the Drug Discovery Process: current status and future prospects

The Role of the Medicinal Chemist in the Drug Discovery Process: current status and future prospects By Dr Stevan W Djuric The need for the pharmaceutical industry to produce a constant stream of new NCEs has never been more paramount but with constantly changing R&D paradigms what is the role… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Lead discovery #Orphan drugs #Regulatory #RNA

Personalised Medicine: What’s in it for big pharma?

Personalised Medicine: What's in it for big pharma? By Dr Stephen Little There is nothing more difficult to take in hand, more perilous to conduct, or more uncertain in its success, than to take the lead in the introduction of a new order of things. Because the innovator has far… Read More

#Archive

#Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Lead discovery #Molecular medicine #RNA #Therapeutics #Toxicology

Next Generation HIV Drugs move into late stage development

Next Generation HIV Drugs move into late stage development By Dr Graham P. Allaway and Dr Jeffrey M. Jacobson There are currently 24 drugs approved for treating HIV infection. Of these, 23 are small molecule orally available drugs, or drug combinations, targeting the virus' reverse transcriptase and protease enzymes, targets… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #PCR #Preclinical #RNA #Screening #Therapeutics

Building a uHTS laboratory communications from the frontier

Building a uHTS laboratory communications from the frontier By Dr Peter Hodder Through sheer commercial need to conduct HTS reliably, rapidly and economically, science and technology have partnered to move laboratories from semi-automated craft guilds to industrialised uHTS research operations. To the benefit of both the pharmaceutical and HTS technology… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #RNA #Screening #Stem cells #Target validation #Toxicology #Translational #Translational chemistry

Automated Patch Clamping: Setting a new standard for early hERG

Share Share Tweet Email Automated Patch Clamping: Setting a new standard for early hERG Automated Patch Clamping: Setting a new standard for early hERG By Dr John Comley Ion channel targets remain a top priority for many Pharma and Biotechs with most looking to increase their screening efforts in 2006. Read More

#Archive

#AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Immunology / Virology & Vaccines #Lead discovery #Oncology #Preclinical #RNA #Stem cells #Therapeutics

Immunomodulation: emerging from obscurity into a major therapeutic class

Immunomodulation: emerging from obscurity into a major therapeutic class By David Gee While not initially apparent, immunomodulation is high on the pharma agenda if recent deal making is a valid indicator. This article discusses the potential of immunomodulation to rise from the relative obscurity of adjuvants in vaccines to mainstream… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Molecular medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Advances in the imaging of biomolecules: the label-free intrinsic imaging approach

Advances in the imaging of biomolecules: the label-free intrinsic imaging approach By Dr Stuart Hassard, Dr Anthony D. Baxter and Dr John Hassard Many stages in the process of drug discovery require the separation, identification and analysis of biomolecules such as proteins, peptides and nucleic acids. Such analyses have traditionally… Read More

#Archive